Northern Trust
BMY.RT

Northern Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Northern Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-830,773
Closed -$573K – 4551
2020
Q4 		$573K Sell
830,773
-1,221
-0.1% -$2.6K ﹤0.01% 3689
2020
Q3 		$1.87M Sell
831,994
-32,426
-4% -$92.6K ﹤0.01% 3098
2020
Q2 		$3.1M Sell
864,420
-56,958
-6% -$205K ﹤0.01% 2802
2020
Q1 		$3.5M Sell
921,378
-31,255
-3% -$103K ﹤0.01% 2503
2019
Q4 		$2.87M Buy
+952,633
New +$2.48M ﹤0.01% 2911

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Northern Trust's BMY.RT Position: Q1 2021 in Review

Northern Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 830,773 shares — an estimated $573K sold.

Northern Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.5M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Northern Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Northern Trust sold 830,773 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $573K.
  • Northern Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Northern Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.5M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Northern Trust's 13F filing for Q1 2021, filed 12 May 2021.